Video Series

Carrie Jardine leads a discussion on varying prior authorization policies for alternative therapies for TRD along with implications to patients.

Our panel concludes with their plans to incorporate RWE into MM management in the future.

Dr Baljević discusses unmet needs that are typically seen in the management of MM.

Dr Brinton highlights the importance of adjunct therapies in LDL management.

Dr Riddock explains how the ASCVD treatment landscape lends itself to initiation of therapy beyond statins in the inpatient setting.

Dr Lopes, OB-GYN and payer, discusses a focus on screening and prevention and availability of contraception among health plans in women’s health.

Ayman Al-Hendy, MD, PhD and Maria Lopes, MD, MS discuss common concerns that women seek care for during their reproductive years, including uterine fibroids, endometriosis, and unintended pregnancy.

Key opinion leaders discuss navigation through challenges with appropriate coding for TRD treatment.

Carrie Jardine and Martin Rosenzweig, MD, share considerations for benefit design in behavioral health.

Eliot Brinton, MD, provides a warning concerning “maximally-tolerated statin dosing” and provides general guidance for optimal dosing.

Ian Riddock, MD, describes the high-risk patient with ASCVD that is appropriate for early intensive lipid lowering.

Dr Richter delves into how we can better educate patients and physicians on RWE to improve decision-making.

The panel moves the discussion to non-comparative RWE and how that can play a part in their decision-making for MM therapy.

Experts in behavioral health discuss overcoming barriers to access for alternative therapies for TRD including the Risk Evaluation and Mitigation Strategy (REMS) requirement for intranasal esketamine.

Dr Patricia Ares-Romero and Dr Martin Rosenzweig discuss treatment strategies for TRD, including alternative therapies and explain current barriers within the healthcare system that inhibit access.

Dr Beveridge explains potential barriers a physician can encounter when implementing RWE into MM therapy.

The panel elaborate on how they’ve incorporated RWE into their decision-making processes for their patients with MM.

Kristin Highland, MD, discusses the common risk factors associated with ILD.

Paul Noble, MD, and Daniel Culver, DO, explain the definition of interstitial lung disease (ILD), as well as certain conditions that fall within that distinction.

Ian Riddock, MD, describes residual cardiovascular risk, both with and without the use of statin therapies.

An expert advises how to optimize the care continuum for patients with ASCVD.

Dr Ian Riddock explains the patient journey post-myocardial infarction (MI), from hospital to outpatient care.

Ian Riddock, MD, discusses the burden of atherosclerotic cardiovascular disease (ASCVD) and multi-societal guideline recommendations for lipid management.

Drs Samuel Nordberg, Patricia Ares-Romero, and Martin Rosenzweig share considerations for effective care delivery for patients with TRD.

Experts in behavioral health discuss therapeutic options for TRD and considerations for defining value.

Jay Weaver, PharmD, MPH, and Muhamed Baljević, MD, FACP, discuss how RWE can affect the management of MM.

Dr Richter relays some of the differences between real-world evidence (RWE) and RCT data, as well as how they can work together when determining therapy.

Dr Samuel Nordberg and Carrie Jardine discuss barriers to access to care for patients with TRD and provide insight on addressing these concerns to achieve optimal care.

Dr. Samuel Nordberg discusses methods for identifying patients in need of an alternative therapy for TRD at the health system level.

Dr Baljević explain some of the limitations physicians can come across with applying randomized clinical trial (RCT) data to MM treatment.